Patents by Inventor Heather Coate

Heather Coate has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7700594
    Abstract: Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: April 20, 2010
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Xin Chen, Heather Coate, Andrew Philip Crew, Han-Qing Dong, Ayako Honda, Mark Joseph Mulvihill, Paula A. R. Tavares, Jing Wang, Douglas S. Werner, Kristen Michelle Mulvihill, Kam W. Siu, Bijoy Panicker, Apoorba Bharadwaj, Lee D. Arnold, Meizhong Jin, Brian Volk, Qinghua Weng, James David Beard
  • Publication number: 20090325928
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: August 12, 2009
    Publication date: December 31, 2009
    Inventors: Lee D. Arnold, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark Joseph Mulvihill, Anthony Nigro, Bijoy Panicker, Arno G. Steinig, Qingua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
  • Publication number: 20090197862
    Abstract: 2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: February 4, 2009
    Publication date: August 6, 2009
    Inventors: Arno G. Steinig, Mark J. Mulvihill, Jing Wang, Douglas S. Werner, Qinghua Weng, Julie Kan, Heather Coate, Xin Chen
  • Publication number: 20090163468
    Abstract: Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
    Type: Application
    Filed: December 2, 2008
    Publication date: June 25, 2009
    Inventors: Xin Chen, Heather Coate, Andrew Philip Crew, Han-Qing Dong, Ayako Honda, Mark Joesph Mulvihill, Paula A.R. Tavares, Jing Wang, Douglas S. Werner, Kristen Michelle Mulvihill, Kam W. Siu, Bijoy Panicker, Apoorba Bharadwaj, Lee D. Arnold, Meizhong Jin, Brian Volk, Qinghua Weng, James David Beard
  • Publication number: 20090118499
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: October 3, 2008
    Publication date: May 7, 2009
    Inventors: Lee D. Arnold, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark Joseph Mulvihill, Anthony Nigro, Bijoy Panicker, Arno G. Steinig, Quinghua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
  • Publication number: 20070112005
    Abstract: Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
    Type: Application
    Filed: November 15, 2006
    Publication date: May 17, 2007
    Inventors: Xin Chen, Heather Coate, Andrew Crew, Han-Qing Dong, Ayako Honda, Mark Mulvihill, Paula Tavares, Jing Wang, Douglas Werner, Kristen Mulvihill, Kam Siu, Bijoy Panicker, Apoorba Bharadwaj, Lee Arnold, Meizhong Jin, Brian Volk, Qinghua Weng, James Beard
  • Publication number: 20060235031
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: March 31, 2005
    Publication date: October 19, 2006
    Inventors: Lee Arnold, Heather Coate, Andrew Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Mulvihill, Mark Mulvihill, Anthony Nigro, Bijoy Panicker, Arno Steinig, Qingua Weng, Douglas Werner, Michael Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun